Reports
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States
Americas
Future Market Insights, Inc.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States
MEA
Future Market Insights
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom
Asia Pacific
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045, India
[426 Pages Report] The global demand for drug formulation is expected to increase at 5.6% CAGR over the forecast period from 2022 to 2032. The sales of the drug formulations market are estimated to reach a valuation of US$ 1.58 Trillion by 2022. According to the study, oral formulations projects to grow exponentially with a CAGR of 6.0% during the forecast period.
Market Outlook:
Data Points | Market Insights |
---|---|
Drug Formulation Market Value 2021 | US$ 1.50 Trillion |
Drug Formulation Market Value 2022 | US$ 1.58 Trillion |
Drug Formulation Market Value 2032 | US$ 2.87 Trillion |
Drug Formulation Market CAGR 2022 to 2032 | 5.6% |
Market Share of Top 5 Countries | 68.4% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights (FMI), the overall sales of drug formulation grew at a CAGR of 5.1% between 2012 and 2021. However, the demand in the drug formulation market is expected to increase at a CAGR of 5.6%, surpassing US$ 2.87 Trillion by the end of 2032.
The pharmaceutical industry has experienced a substantial revolution with the introduction of novel technologies as well as more affordable and cost-effective manufacturing methods. Robotics and artificial intelligence are increasingly being used in the pharmaceutical industry to decrease production waste and downtime on the factory floor. Personalized medicine's continual breakthroughs have also made it feasible to establish patient-centric models by opening up several chances to address a wide range of medical conditions.
In addition, the growing prevalence of the chronic disease among the population, and rising investment flow in this sector are positively driving the market growth. The consumption of pharmaceuticals is also being influenced by the growing world population, which has helped the drug formulation industry rise recently. As a result, the use of antidepressants doubled, consumption of antihypertensive and antidiabetic medications almost doubled, and consumption of cholesterol-lowering medications nearly quadrupled between 2000 and 2015 in Organization for Economic Cooperation and Development (OECD) nations. Increasing the focus on non-communicable diseases (NCDs), such as diabetes and hypertension, which are already widespread in developed nations, while communicable diseases, such as Acquired immunodeficiency syndrome (AIDS), malaria, and tuberculosis, which affect many developing economies, continue to exist.
The global drug formulation market is expected to be valued at US$ 2.87 Trillion by the end of 2032, registering a CAGR of 5.6% in the forecast period.
Until the 20th century, there were relatively limited medicines and treatment options available for chronic diseases like cancer or other rare diseases which indeed projected limited treatment options. However, the growth in research efforts and investment for drug development has projected a positive impact projecting an opportunistic factor for the manufacturers for new drug development in the market. The opportunities are growing because of the increasing advances in molecular biology to develop new agents.
The amount of revenue that pharmaceutical companies anticipate gaining from a new drug, the estimated cost of developing that drug, and laws that affect the supply and demand for drugs also play a role in the amounts of money they invest in research and development (Research and Development). For instance, according to Federal Government Statistics, pharmaceutical businesses invested an average of about 25% of their revenue in Research and Development. In 2019, Top Research and Development spenders 2021 spent close to one-fifth of their income on Research and Development. The pharmaceutical industry is undoubtedly a global one, although US-based businesses often spend the most on Research and Development. Such conditions are anticipated to create lucrative opportunities for local players to reinforce their position and increase their market share over the forecast period.
Currently, trial and error procedures are used to generate pharmaceutical compositions. This process is a time-consuming method that takes a long time to complete, involving high expenses, and a significant amount of work labors to build and maintain. However, complexity in compliance with the regulatory values would impact the drug development process, if the formulation is unable to comply with the regulatory requirement the repeat process for drug development would negatively impact the pharmaceutical industry economy to a high extent. The pharmaceutical sector is under pressure to lower healthcare costs and the production of new active pharmaceutical ingredients (APIs). Thus this factor expects to restrain the pharmaceutical industries to involve in the drug development process which in turn expects to hamper the market growth.
Additionally, complexity in the supply chain exists to be a restricting factor expected to hamper the drug formulation market growth. Most pharmaceutical companies have a complex supply chain, which is either inefficient or under-utilized. The complexity of the supply chain is due to low flexibility or its cost-effective nature. However, increasing generic competition has dented the profitability of big players and the trend expects to continue over the years. Many pharmaceutical companies have started to reorganize their supply chain in response to changing market structures, but these changes are only meant to address short-term challenges. Along with patent cliffs, the shortening of effective patent life is the major issue in the drug formulation market due to increasing time-to-market and stringent regulations.
According to Future Market Insights, the US witnessed dominance in the North American drug formulation market, accounting for the highest total market share of 91.3% in 2021, and is projected to continue to exhibit high growth through 2022 & beyond.
The worldwide pharmaceutical market is significantly supported by the US market. Growing Research and Development spending has sped up FDA approvals, which are expected to remain stable until 2021. In 2021, the government approved 50 innovative medications, which was broadly in pace with the approval of 53 drugs the year before.
According to FMI Analysis, US pharmaceutical production and sales are expected to continue strong due to the ongoing global vaccination campaign and the accumulated demand for both necessary and optional medical treatments in 2022.
Germany is set to exhibit growth at a CAGR of around 5.2% in the Europe drug formulation market during the forecast period. The German healthcare industry is heavily controlled, and pharmaceutical companies do not face a lot of legal pressure to cut their drug sales prices for final consumers exploring opportunities for new entrance and positive opportunities for the existing manufacturers to invest and develop products in the market. Additionally, the presence of major players like Boehringer Ingelheim International Gmbh, Bayer AG, Merck KGa, Fresenius Kabi, and many more expect to augment the production capacity and make high product availability in the market witnessing the country’s dominance in the Europe market.
China is projected to expand at a CAGR rate of 7.3% and is anticipated to account the half of the East Asia drug formulation marker revenue valued to reach around US$ 320.7 Billion in 2032.
The pharmaceutical industry in China is also very fragmented; most producers are small and medium-sized businesses. As a result, Research and Development investment is modest in comparison to international competitors. By 2025, the 14th Five-Year Plan wants to raise spending to 10% of sales. Pharmaceutical multinational companies (MNCs) with large market positions include AstraZeneca, Novartis, and Novo Nordisk, each of which held between 8 and 10% of the domestic market share in 2019. Since distribution networks are so important to the industry, domestic pharmaceutical companies like Sinopharm and Shanghai Pharmaceuticals have a firm grip on them. The government has been attempting to consolidate the pharmaceutical business and raise the average size of firms as a result of the industry's fragmentation to assist in quality inspection and improvement.
Major medical reforms have also been implemented in order to advance the development and maturity of China's pharmaceutical industry, in addition to the aforementioned policy changes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The oral formulation contribute about 42.2% of the market share in 2021 and is expected to register a CAGR of 6.0% in the forecast period. Oral formulations are highly preferred over other dosage forms owing to their advantageous factors, including patient compliance, non-invasiveness, and ease of drug administration.
Central Nervous System Disorders are expected to hold more than a 14% market share, exhibiting growth at 3.1% CAGR in the forecast period.
The growing prevalence of central nervous system disorders among the growing population has surged the demand for novel drugs in the market intending to explore opportunities in the market. For instance, the development of novel biologic drugs, such as recombinant proteins or gene therapies, is essential for the treatment of Alzheimer's disease (AD) and the therapy of the aging brain.
Based on end user, the big pharma companies held the highest market share of 39.9% in 2021 and is poised to expand at a CAGR of 5.1% over the upcoming decade. Big pharma companies with well-structured research and development sector along with high investment in product development and innovation has accelerated the production capacity of novel drug formulations.
Key manufacturers are implementing strategies in the drug formulation market, including mergers and acquisitions and advanced product launches by acquiring approvals. To acquire a competitive edge in the market, the key companies are focusing on collaborating with the research institutes.
Attribute | Details |
---|---|
Forecast Period | 2022 to 2032 |
Historical Data Available for | 2012 to 2021 |
Market Analysis | US$ Billion for Value |
Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
Key Countries Covered | US, Canada, Brazil, Mexico, Argentina, UK, Germany, France, Italy, Spain, Russia, BENELUX, China, Japan, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, North Africa, GCC Countries, Turkey, Egypt, and South Africa |
Key Market Segments Covered | Dosage form, Indication, End User, and Region |
Key Companies Profiled |
|
Pricing | Available upon Request |
1. Executive Summary | Drug Formulation Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusion and Exclusion 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Key Inclusion 4.1. Product Adoption / Consumption Analysis 4.2. Key Promotional Strategies, By Manufacturers 4.3. Disease Epidemiology 4.4. Pipeline Assessment 4.5. Regulatory Landscape 4.6. Reimbursement Outlook 4.7. PESTLE Analysis 4.8. Porter’s Analysis 4.9. Supply Chain Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Industry Market Outlook 5.1.3. Pharmaceutical Industry Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rise In Incidence of chronic disease 5.2.2. Growth In Production Capacity 5.2.3. Increase In Adoption Rate 5.2.4. Increasing Economic Affluence In Emerging Economies 5.2.5. Distribution Channel 5.2.6. Cost Consideration 5.2.7. Regulatory Scenario 5.2.8. Growing Geriatric Population 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. Current COVID-19 Statistics and Probable Future Impact 6.2. COVID-19 and Impact Analysis 6.2.1. Revenue By Dosage Form 6.2.2. Revenue By Indication 6.2.3. Revenue By End User 6.2.4. Revenue By Country 7. Global Drug Formulation Market Demand (in Value US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032 7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021 7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2012 to 2021 8.3. Current and Future Market Size (US$ Million) Analysis By Dosage Form, 2022 to 2032 8.3.1. Oral formulations 8.3.1.1. Tablets 8.3.1.1.1. Immediate Release 8.3.1.1.2. Modified Release 8.3.1.1.3. Chewable 8.3.1.1.4. Effervescent 8.3.1.2. Capsules 8.3.1.2.1. Hard Gelatin Capsules 8.3.1.2.2. Softgel Capsules 8.3.1.3. Powders & Granules 8.3.1.4. Lozenges & Pastilles 8.3.1.5. Gummies 8.3.1.6. Others 8.3.2. Parenteral formulations 8.3.2.1. Solutions 8.3.2.2. Suspensions 8.3.2.3. Emulsions for injection or infusion 8.3.2.4. Powders for injection or infusion 8.3.2.5. Gels for injection implants 8.3.3. Topical formulations 8.3.3.1. Pastes 8.3.3.2. Ointments and oils 8.3.3.3. Creams, lotions, and foams. 8.3.3.4. Gels, tinctures, and powders. 8.3.3.5. Sprays and patches. 8.3.4. Inhalation formulations 8.3.4.1. Pressurized Metered Dose Inhaler 8.3.4.2. Dry Powder Inhaler (DPI) 8.3.4.3. Nebulizer 8.4. Market Attractiveness Analysis By Dosage Form 9. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Indication, 2012 to 2021 9.3. Current and Future Market Size (US$ Million) Analysis Forecast By Indication, 2022 to 2032 9.3.1. Infectious Diseases 9.3.2. Cancer 9.3.3. Cardiovascular Diseases 9.3.4. Diabetes 9.3.5. Respiratory Diseases 9.3.6. Central Nervous System Disorders 9.3.7. Autoimmune Diseases 9.3.8. Gastrointestinal Disease 9.3.9. Musculoskeletal disorders 9.3.10. Dermatology disorders 9.3.11. Others 9.4. Market Attractiveness Analysis By Indication 10. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2021 10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032 10.3.1. Big pharma 10.3.2. Small & Medium Size Pharma- Companies 10.3.3. Biotech Companies 10.4. Market Attractiveness Analysis By End User 11. Global Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region 11.1. Introduction 11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021 11.3. Current and Future Market Size (US$ Million) Analysis Forecast By Region, 2022 to 2032 11.3.1. North America 11.3.2. Latin America 11.3.3. Europe 11.3.4. South Asia 11.3.5. East Asia 11.3.6. Oceania 11.3.7. Middle East & Africa (MEA) 11.4. Market Attractiveness Analysis By Region 12. North America Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 12.1. Introduction 12.2. Historical Market Size (US$ Million) By Market Taxonomy, 2012 to 2021 12.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 12.3.1. By Country 12.3.1.1. US 12.3.1.2. Canada 12.3.2. By Dosage Form 12.3.3. By Indication 12.3.4. By End User 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Dosage Form 12.4.3. By Indication 12.4.4. By End User 12.5. Key Market Participants - Intensity Mapping 12.6. Country-Level Analysis & Forecast 12.6.1. U.S. Drug Formulation Market 12.6.1.1. Introduction 12.6.1.2. Market Analysis and Forecast By Market Taxonomy 12.6.1.2.1. By Dosage Form 12.6.1.2.2. By Indication 12.6.1.2.3. By End User 12.6.2. Canada Drug Formulation Market 12.6.2.1. Introduction 12.6.2.2. Market Analysis and Forecast By Market Taxonomy 12.6.2.2.1. By Dosage Form 12.6.2.2.2. By Indication 12.6.2.2.3. By End User 13. Latin America Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 13.1. Introduction 13.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 13.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 13.3.1. By Country 13.3.1.1. Brazil 13.3.1.2. Mexico 13.3.1.3. Argentina 13.3.1.4. Rest of Latin America 13.3.2. By Dosage Form 13.3.3. By Indication 13.3.4. By End User 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Dosage Form 13.4.3. By Indication 13.4.4. By End User 13.5. Key Market Participants - Intensity Mapping 13.6. Country-Level Analysis & Forecast 13.6.1. Brazil Drug Formulation Market 13.6.1.1. Introduction 13.6.1.2. Market Analysis and Forecast By Market Taxonomy 13.6.1.2.1. By Dosage Form 13.6.1.2.2. By Indication 13.6.1.2.3. By End User 13.6.2. Mexico Drug Formulation Market 13.6.2.1. Introduction 13.6.2.2. Market Analysis and Forecast By Market Taxonomy 13.6.2.2.1. By Dosage Form 13.6.2.2.2. By Indication 13.6.2.2.3. By End User 13.6.3. Argentina Drug Formulation Market 13.6.3.1. Introduction 13.6.3.2. Market Analysis and Forecast By Market Taxonomy 13.6.3.2.1. By Dosage Form 13.6.3.2.2. By Indication 13.6.3.2.3. By End User 14. Europe Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 14.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 14.3.1. By Country 14.3.1.1. Germany 14.3.1.2. Italy 14.3.1.3. France 14.3.1.4. The UK 14.3.1.5. Spain 14.3.1.6. BENELUX 14.3.1.7. Russia 14.3.1.8. Rest of Europe 14.3.2. By Dosage Form 14.3.3. By Indication 14.3.4. By End User 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Dosage Form 14.4.3. By Indication 14.4.4. By End User 14.5. Key Market Participants - Intensity Mapping 14.6. Country-Level Analysis & Forecast 14.6.1. Germany Drug Formulation Market 14.6.1.1. Introduction 14.6.1.2. Market Analysis and Forecast By Market Taxonomy 14.6.1.2.1. By Dosage Form 14.6.1.2.2. By Indication 14.6.1.2.3. By End User 14.6.2. Italy Drug Formulation Market 14.6.2.1. Introduction 14.6.2.2. Market Analysis and Forecast By Market Taxonomy 14.6.2.2.1. By Dosage Form 14.6.2.2.2. By Indication 14.6.2.2.3. By End User 14.6.3. France Drug Formulation Market 14.6.3.1. Introduction 14.6.3.2. Market Analysis and Forecast By Market Taxonomy 14.6.3.2.1. By Dosage Form 14.6.3.2.2. By Indication 14.6.3.2.3. By End User 14.6.4. U.K. Drug Formulation Market 14.6.4.1. Introduction 14.6.4.2. Market Analysis and Forecast By Market Taxonomy 14.6.4.2.1. By Dosage Form 14.6.4.2.2. By Indication 14.6.4.2.3. By End User 14.6.5. Spain Drug Formulation Market 14.6.5.1. Introduction 14.6.5.2. Market Analysis and Forecast By Market Taxonomy 14.6.5.2.1. By Dosage Form 14.6.5.2.2. By Indication 14.6.5.2.3. By End User 14.6.6. BENELUX Drug Formulation Market 14.6.6.1. Introduction 14.6.6.2. Market Analysis and Forecast By Market Taxonomy 14.6.6.2.1. By Dosage Form 14.6.6.2.2. By Indication 14.6.6.2.3. By End User 14.6.7. Russia Drug Formulation Market 14.6.7.1. Introduction 14.6.7.2. Market Analysis and Forecast By Market Taxonomy 14.6.7.2.1. By Dosage Form 14.6.7.2.2. By Indication 14.6.7.2.3. By End User 15. South Asia Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 15.3. Current and Future Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Thailand 15.3.1.3. Indonesia 15.3.1.4. Malaysia 15.3.1.5. Rest of South Asia 15.3.2. By Dosage Form 15.3.3. By Indication 15.3.4. By End User 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Dosage Form 15.4.3. By Indication 15.4.4. By End User 15.5. Key Market Participants - Intensity Mapping 15.6. Country-Level Analysis & Forecast 15.6.1. India Drug Formulation Market 15.6.1.1. Introduction 15.6.1.2. Market Analysis and Forecast By Market Taxonomy 15.6.1.2.1. By Dosage Form 15.6.1.2.2. By Indication 15.6.1.2.3. By End User 15.6.2. Thailand Drug Formulation Market 15.6.2.1. Introduction 15.6.2.2. Market Analysis and Forecast By Market Taxonomy 15.6.2.2.1. By Dosage Form 15.6.2.2.2. By Indication 15.6.2.2.3. By End User 15.6.3. Indonesia Drug Formulation Market 15.6.3.1. Introduction 15.6.3.2. Market Analysis and Forecast By Market Taxonomy 15.6.3.2.1. By Dosage Form 15.6.3.2.2. By Indication 15.6.3.2.3. By End User 15.6.4. Malaysia Drug Formulation Market 15.6.4.1. Introduction 15.6.4.2. Market Analysis and Forecast By Market Taxonomy 15.6.4.2.1. By Dosage Form 15.6.4.2.2. By Indication 15.6.4.2.3. By End User 16. East Asia Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 16.3. Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 16.3.1. By Country 16.3.1.1. China 16.3.1.2. Japan 16.3.1.3. South Korea 16.3.2. By Dosage Form 16.3.3. By Indication 16.3.4. By End User 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Dosage Form 16.4.3. By Indication 16.4.4. By End User 16.5. Key Market Participants - Intensity Mapping 16.6. Country-Level Analysis & Forecast 16.6.1. China Drug Formulation Market 16.6.1.1. Introduction 16.6.1.2. Market Analysis and Forecast By Market Taxonomy 16.6.1.2.1. By Dosage Form 16.6.1.2.2. By Indication 16.6.1.2.3. By End User 16.6.2. Japan Drug Formulation Market 16.6.2.1. Introduction 16.6.2.2. Market Analysis and Forecast By Market Taxonomy 16.6.2.2.1. By Dosage Form 16.6.2.2.2. By Indication 16.6.2.2.3. By End User 16.6.3. South Korea Drug Formulation Market 16.6.3.1. Introduction 16.6.3.2. Market Analysis and Forecast By Market Taxonomy 16.6.3.2.1. By Dosage Form 16.6.3.2.2. By Indication 16.6.3.2.3. By End User 17. Oceania Drug Formulation Market Analysis 2012 to 2021 and Forecast 2022 to 2032 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 17.3. Market Size (US$ Million) By Market Taxonomy, 2022 to 2032 17.3.1. By Country 17.3.1.1. Australia 17.3.1.2. New Zealand 17.3.2. B By Dosage Form 17.3.3. By Indication 17.3.4. By End User 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Dosage Form 17.4.3. By Indication 17.4.4. By End User 17.5. Country-Level Analysis & Forecast 17.5.1. Australia Drug Formulation Market 17.5.1.1. Introduction 17.5.1.2. Market Analysis and Forecast By Market Taxonomy 17.5.1.2.1. By Dosage Form 17.5.1.2.2. By Indication 17.5.1.2.3. By End User 17.5.2. New Zealand Drug Formulation Market 17.5.2.1. Introduction 17.5.2.2. Market Analysis and Forecast By Market Taxonomy 17.5.2.2.1. By Dosage Form 17.5.2.2.2. By Indication 17.5.2.2.3. By End User 18. Middle East and Africa Drug Formulation Market Analysis 2012 to 2021and Forecast 2022 to 2032 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2012 to 2021 18.3. Market Size (US$ Million) Forecast By Market Taxonomy, 2022 to 2032 18.3.1. By Country 18.3.1.1. GCC Countries 18.3.1.2. Turkey 18.3.1.3. Israel 18.3.1.4. South Africa 18.3.1.5. North Africa 18.3.1.6. Rest of Middle East and Africa 18.3.2. By Dosage Form 18.3.3. By Indication 18.3.4. By End User 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Dosage Form 18.4.3. By Indication 18.4.4. By End User 18.5. Key Market Participants - Intensity Mapping 18.6. Country-Level Analysis & Forecast 18.6.1. GCC Countries Drug Formulation Market 18.6.1.1. Introduction 18.6.1.2. Market Analysis and Forecast By Market Taxonomy 18.6.1.2.1. By Dosage Form 18.6.1.2.2. By Indication 18.6.1.2.3. By End User 18.6.2. Turkey Drug Formulation Market 18.6.2.1. Introduction 18.6.2.2. Market Analysis and Forecast By Market Taxonomy 18.6.2.2.1. By Dosage Form 18.6.2.2.2. By Indication 18.6.2.2.3. By End User 18.6.3. Egypt Drug Formulation Market 18.6.3.1. Introduction 18.6.3.2. Market Analysis and Forecast By Market Taxonomy 18.6.3.2.1. By Dosage Form 18.6.3.2.2. By Indication 18.6.3.2.3. By End User 18.6.4. South Africa Drug Formulation Market 18.6.4.1. Introduction 18.6.4.2. Market Analysis and Forecast By Market Taxonomy 18.6.4.2.1. By Dosage Form 18.6.4.2.2. By Indication 18.6.4.2.3. By End User 18.6.5. North Africa Drug Formulation Market 18.6.5.1. Introduction 18.6.5.2. Market Analysis and Forecast By Market Taxonomy 18.6.5.2.1. By Dosage Form 18.6.5.2.2. By Indication 18.6.5.2.3. By End User 19. Market Structure Analysis 19.1. Market Analysis By Tier of Companies 19.2. Market Share Analysis of Top Players 19.3. Market Presence Analysis 20. Competition Analysis 20.1. Competition Dashboard 20.2. Competition Deep Dive 20.2.1. AstraZeneca plc. 20.2.1.1. Overview 20.2.1.2. Product Portfolio 20.2.1.3. SWOT Analysis 20.2.1.4. Strategy Overview 20.2.1.4.1. Marketing Strategies 20.2.1.4.2. Product Strategies 20.2.1.4.3. Channel Strategies 20.2.2. Bristol-Myers Squibb 20.2.2.1. Overview 20.2.2.2. Product Portfolio 20.2.2.3. SWOT Analysis 20.2.2.4. Strategy Overview 20.2.2.4.1. Marketing Strategies 20.2.2.4.2. Product Strategies 20.2.2.4.3. Channel Strategies 20.2.3. Eli Lilly and Company 20.2.3.1. Overview 20.2.3.2. Product Portfolio 20.2.3.3. SWOT Analysis 20.2.3.4. Strategy Overview 20.2.3.4.1. Marketing Strategies 20.2.3.4.2. Product Strategies 20.2.3.4.3. Channel Strategies 20.2.4. Gilead Sciences, Inc. 20.2.4.1. Overview 20.2.4.2. Product Portfolio 20.2.4.3. SWOT Analysis 20.2.4.4. Strategy Overview 20.2.4.4.1. Marketing Strategies 20.2.4.4.2. Product Strategies 20.2.4.4.3. Channel Strategies 20.2.5. Merck & Co., Inc. 20.2.5.1. Overview 20.2.5.2. Product Portfolio 20.2.5.3. SWOT Analysis 20.2.5.4. Strategy Overview 20.2.5.4.1. Marketing Strategies 20.2.5.4.2. Product Strategies 20.2.5.4.3. Channel Strategies 20.2.6. Novartis AG 20.2.6.1. Overview 20.2.6.2. Product Portfolio 20.2.6.3. SWOT Analysis 20.2.6.4. Strategy Overview 20.2.6.4.1. Marketing Strategies 20.2.6.4.2. Product Strategies 20.2.6.4.3. Channel Strategies 20.2.7. Pfizer Inc. 20.2.7.1. Overview 20.2.7.2. Product Portfolio 20.2.7.3. SWOT Analysis 20.2.7.4. Strategy Overview 20.2.7.4.1. Marketing Strategies 20.2.7.4.2. Product Strategies 20.2.7.4.3. Channel Strategies 20.2.8. AbbVie Inc. 20.2.8.1. Overview 20.2.8.2. Product Portfolio 20.2.8.3. SWOT Analysis 20.2.8.4. Strategy Overview 20.2.8.4.1. Marketing Strategies 20.2.8.4.2. Product Strategies 20.2.8.4.3. Channel Strategies 20.2.9. Boehringer Ingelheim International GmbH 20.2.9.1. Overview 20.2.9.2. Product Portfolio 20.2.9.3. SWOT Analysis 20.2.9.4. Strategy Overview 20.2.9.4.1. Marketing Strategies 20.2.9.4.2. Product Strategies 20.2.9.4.3. Channel Strategies 20.2.10. F. Hoffmann-La Roche AG 20.2.10.1. Overview 20.2.10.2. Product Portfolio 20.2.10.3. SWOT Analysis 20.2.10.4. Strategy Overview 20.2.10.4.1. Marketing Strategies 20.2.10.4.2. Product Strategies 20.2.10.4.3. Channel Strategies 20.2.11. Johnson & Johnson 20.2.11.1. Overview 20.2.11.2. Product Portfolio 20.2.11.3. SWOT Analysis 20.2.11.4. Strategy Overview 20.2.11.4.1. Marketing Strategies 20.2.11.4.2. Product Strategies 20.2.11.4.3. Channel Strategies 20.2.12. 3M Company 20.2.12.1. Overview 20.2.12.2. Product Portfolio 20.2.12.3. SWOT Analysis 20.2.12.4. Strategy Overview 20.2.12.4.1. Marketing Strategies 20.2.12.4.2. Product Strategies 20.2.12.4.3. Channel Strategies 20.2.13. Bayer AG 20.2.13.1. Overview 20.2.13.2. Product Portfolio 20.2.13.3. SWOT Analysis 20.2.13.4. Strategy Overview 20.2.13.4.1. Marketing Strategies 20.2.13.4.2. Product Strategies 20.2.13.4.3. Channel Strategies 20.2.14. Teva Pharmaceuticals Industries Ltd. 20.2.14.1. Overview 20.2.14.2. Product Portfolio 20.2.14.3. SWOT Analysis 20.2.14.4. Strategy Overview 20.2.14.4.1. Marketing Strategies 20.2.14.4.2. Product Strategies 20.2.14.4.3. Channel Strategies 20.2.15. Amgen, Inc. 20.2.15.1. Overview 20.2.15.2. Product Portfolio 20.2.15.3. SWOT Analysis 20.2.15.4. Strategy Overview 20.2.15.4.1. Marketing Strategies 20.2.15.4.2. Product Strategies 20.2.15.4.3. Channel Strategies 20.2.16. Sanofi SA 20.2.16.1. Overview 20.2.16.2. Product Portfolio 20.2.16.3. SWOT Analysis 20.2.16.4. Strategy Overview 20.2.16.4.1. Marketing Strategies 20.2.16.4.2. Product Strategies 20.2.16.4.3. Channel Strategies 20.2.17. GlaxoSmithKline plc 20.2.17.1. Overview 20.2.17.2. Product Portfolio 20.2.17.3. SWOT Analysis 20.2.17.4. Strategy Overview 20.2.17.4.1. Marketing Strategies 20.2.17.4.2. Product Strategies 20.2.17.4.3. Channel Strategies 20.2.18. Boston Scientific Corporation 20.2.18.1. Overview 20.2.18.2. Product Portfolio 20.2.18.3. SWOT Analysis 20.2.18.4. Strategy Overview 20.2.18.4.1. Marketing Strategies 20.2.18.4.2. Product Strategies 20.2.18.4.3. Channel Strategies 20.2.19. Gerresheimer AG 20.2.19.1. Overview 20.2.19.2. Product Portfolio 20.2.19.3. SWOT Analysis 20.2.19.4. Strategy Overview 20.2.19.4.1. Marketing Strategies 20.2.19.4.2. Product Strategies 20.2.19.4.3. Channel Strategies 20.2.20. Nimbus Therapeutics 20.2.20.1. Overview 20.2.20.2. Product Portfolio 20.2.20.3. SWOT Analysis 20.2.20.4. Strategy Overview 20.2.20.4.1. Marketing Strategies 20.2.20.4.2. Product Strategies 20.2.20.4.3. Channel Strategies 20.2.21. Antares Pharma, Inc. 20.2.21.1. Overview 20.2.21.2. Product Portfolio 20.2.21.3. SWOT Analysis 20.2.21.4. Strategy Overview 20.2.21.4.1. Marketing Strategies 20.2.21.4.2. Product Strategies 20.2.21.4.3. Channel Strategies 20.2.22. IDEAYA Biosciences, Inc. 20.2.22.1. Overview 20.2.22.2. Product Portfolio 20.2.22.3. SWOT Analysis 20.2.22.4. Strategy Overview 20.2.22.4.1. Marketing Strategies 20.2.22.4.2. Product Strategies 20.2.22.4.3. Channel Strategies 21. Assumptions and Acronyms Used 22. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Table 01: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 02: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 03: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 04: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 05: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 06: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 07: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 08: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 09: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region Table 10: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Region Table 11: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 12: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 13: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 14: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 15: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 16: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 17: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 18: North America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 19: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 20: Global Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 20 :Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 21: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 22: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 23: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 24: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 25: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 26: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 27: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 28: Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 30 :Latin America Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 31 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 32 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 33 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 34: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 35: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 36 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 37: Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 38 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 39 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 40 : Europe Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 41 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 42 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 43: South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 44 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 45 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 46 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 47 :South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 48 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 49 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 50 : South Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 51: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 52: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 53 :East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 54: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 55: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 56: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 57: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 58: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 59: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 60: East Asia Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 61: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 62: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 63 :Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 64 :Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 65: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 66: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 67 : Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 68 : Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 69: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 70: Oceania Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 71 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 72 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Country Table 73 :Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 74 :Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 75 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 76 : Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Dosage Form Table 77: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 78: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By Indication Table 79: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User Table 80: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
Figure 01: Global Drug Formulation Market Size (US$ Mn) 2021A & 2032F Figure 02: Global Drug Formulation Market Share 2021A, By Dosage Form Figure 03: Global Drug Formulation Market Share 2021A, By Indication Figure 04: Global Drug Formulation Market Share 2021A, By End User Figure 05: Global Drug Formulation Market Share 2021A, By Region Figure 06: Global Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 07: Global Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 08: Global Drug Formulation Market Absolute $ Opportunity Analysis, 2022 to 2032 Figure 09: Global Drug Formulation Market Analysis By Dosage Form 2022 to 2032 Figure 10: Global Drug Formulation Market Y-o-Y Growth Projections By Dosage Form, 2022 to 2032 Figure 11: Global Drug Formulation Market Attractiveness, By Dosage Form, 2022 to 2032 Figure 12: Global Drug Formulation Market Analysis By Indication 2021 to 2032 Figure 13: Global Drug Formulation Market Y-o-Y Growth Projections By Indication, 2022 to 2032 Figure 14: Global Drug Formulation Market Attractiveness, By Indication, 2022 to 2032 Figure 15: Global Drug Formulation Market Analysis By End User, 2021 to 2032 Figure 16: Global Drug Formulation Market Y-o-Y Growth Projections By End User, 2022 to 2032 Figure 17: Global Drug Formulation Market Attractiveness, By End User, 2022 to 2032 Figure 18: Global Drug Formulation Market Analysis By Region, 2021 to 2032 Figure 19: Global Drug Formulation Market Y-o-Y Growth Projections By Region, 2022 to 2032 Figure 20: Global Drug Formulation Market Attractiveness, By Region, 2022 to 2032 Figure 21: North America Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 22: North America Drug Formulation Market Value Share, By Indication 2022 (E) Figure 23: North America Drug Formulation Market Value Share, By End User 2022 (E) Figure 24: North America Drug Formulation Market Value Share, By Region 2022 (E) Figure 25: North America Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 26: North America Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 27: North America Drug Formulation Market Attractiveness Analysis, By Country Figure 28: North America Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 29: North America Drug Formulation Market Attractiveness, By Indication Figure 30: North America Drug Formulation Market Attractiveness, By End User Figure 31: US Market Value Proportion Analysis, 2021 Figure 32: Global Vs. US Growth Comparison, 2021 to 2032 Figure 33: US Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 34: US Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 35: US Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 36: Canada Market Value Proportion Analysis, 2021 Figure 37: Global Vs. Canada Growth Comparison, 2021 to 2032 Figure 38: Canada Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 39: Canada Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 40: Canada Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 41: Latin America Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 42: Latin America Drug Formulation Market Value Share, By Indication 2022 (E) Figure 43: Latin America Drug Formulation Market Value Share, By End User 2022 (E) Figure 44: Latin America Drug Formulation Market Value Share, By Region 2022 (E) Figure 45: Latin America Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 46: Latin America Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 47: Latin America Drug Formulation Market Attractiveness Analysis, By Country Figure 48: Latin America Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 49: Latin America Drug Formulation Market Attractiveness, By Indication Figure 50: Latin America Drug Formulation Market Attractiveness, By End User Figure 51: Brazil Market Value Proportion Analysis, 2021 Figure 52: Global Vs. Brazil Growth Comparison, 2021 to 2032 Figure 53: Brazil Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 54: Brazil Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 55: Brazil Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 56: Mexico Market Value Proportion Analysis, 2021 Figure 57: Global Vs. Mexico Growth Comparison, 2021 to 2032 Figure 58: Mexico Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 59: Mexico Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 60: Mexico Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 61: Argentina Market Value Proportion Analysis, 2021 Figure 62: Global Vs. Argentina Growth Comparison, 2021 to 2032 Figure 63: Argentina Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 64: Argentina Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 65: Argentina Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 66: Europe Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 67: Europe Drug Formulation Market Value Share, By Indication 2022 (E) Figure 68: Europe Drug Formulation Market Value Share, By End User 2022 (E) Figure 69: Europe Drug Formulation Market Value Share, By Region 2022 (E) Figure 70: Europe Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 71: Europe Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 72: Europe Drug Formulation Market Attractiveness Analysis, By Country Figure 73: Europe Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 74: Europe Drug Formulation Market Attractiveness, By Indication Figure 75: Europe Drug Formulation Market Attractiveness, By End User Figure 76: UK Market Value Proportion Analysis, 2021 Figure 77: Global Vs. UK Growth Comparison, 2021 to 2032 Figure 78: UK Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 79: UK Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 80: UK Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 81: Germany Market Value Proportion Analysis, 2021 Figure 82: Global Vs. Germany Growth Comparison, 2021 to 2032 Figure 83: Germany Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 84: Germany Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 85: Germany Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 86: Italy Market Value Proportion Analysis, 2021 Figure 87: Global Vs. Italy Growth Comparison, 2021 to 2032 Figure 88: Italy Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 89: Italy Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 90: Italy Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 91: France Market Value Proportion Analysis, 2021 Figure 92: Global Vs. France Growth Comparison, 2021 to 2032 Figure 93: France Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 94: France Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 95: France Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 96: Spain Market Value Proportion Analysis, 2021 Figure 97: Global Vs. Spain Growth Comparison, 2021 to 2032 Figure 98: Spain Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 99: Spain Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 100: Spain Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 101: BENELUX Market Value Proportion Analysis, 2021 Figure 102: Global Vs. BENELUX Growth Comparison, 2021 to 2032 Figure 103: BENELUX Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 104: BENELUX Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 105: BENELUX Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 106: Russia Market Value Proportion Analysis, 2021 Figure 107: Global Vs. Russia Growth Comparison, 2021 to 2032 Figure 108: Russia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 109: Russia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 110: Russia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 111: South Asia Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 112: South Asia Drug Formulation Market Value Share, By Indication 2022 (E) Figure 113: South Asia Drug Formulation Market Value Share, By End User 2022 (E) Figure 114: South Asia Drug Formulation Market Value Share, By Region 2022 (E) Figure 115: South Asia Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 116: South Asia Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 117: South Asia Drug Formulation Market Attractiveness Analysis, By Country Figure 118: South Asia Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 119: South Asia Drug Formulation Market Attractiveness, By Indication Figure 120: South Asia Drug Formulation Market Attractiveness, By End User Figure 121: India Market Value Proportion Analysis, 2021 Figure 122: Global Vs. India Growth Comparison, 2021 to 2032 Figure 123: India Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 124: India Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 125: India Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 126: Malaysia Market Value Proportion Analysis, 2021 Figure 127: Global Vs. Malaysia Growth Comparison, 2021 to 2032 Figure 128: Malaysia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 129: Malaysia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 130: Malaysia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 131: Thailand Market Value Proportion Analysis, 2021 Figure 132: Global Vs. Thailand Growth Comparison, 2021 to 2032 Figure 133: Thailand Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 134: Thailand Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 135: Thailand Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 136: Indonesia Market Value Proportion Analysis, 2021 Figure 137: Global Vs. Indonesia Growth Comparison, 2021 to 2032 Figure 138: Indonesia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 139: Indonesia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 140: Indonesia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 141: East Asia Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 142: East Asia Drug Formulation Market Value Share, By Indication 2022 (E) Figure 143: East Asia Drug Formulation Market Value Share, By End User 2022 (E) Figure 144: East Asia Drug Formulation Market Value Share, By Region 2022 (E) Figure 145: East Asia Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 146: East Asia Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 147: East Asia Drug Formulation Market Attractiveness Analysis, By Country Figure 148: East Asia Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 149: East Asia Drug Formulation Market Attractiveness, By Indication Figure 150: East Asia Drug Formulation Market Attractiveness, By End User Figure 151: China Market Value Proportion Analysis, 2021 Figure 152: Global Vs. China Growth Comparison, 2021 to 2032 Figure 153: China Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 154: China Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 155: China Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 156: Japan Market Value Proportion Analysis, 2021 Figure 157: Global Vs. Japan Growth Comparison, 2021 to 2032 Figure 158: Japan Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 159: Japan Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 160: Japan Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 161: South Korea Market Value Proportion Analysis, 2021 Figure 162: Global Vs. South Korea Growth Comparison, 2021 to 2032 Figure 163: South Korea Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 164: South Korea Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 165: South Korea Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 166: Oceania Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 167: Oceania Drug Formulation Market Value Share, By Indication 2022 (E) Figure 168: Oceania Drug Formulation Market Value Share, By End User 2022 (E) Figure 169: Oceania Drug Formulation Market Value Share, By Region 2022 (E) Figure 170: Oceania Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 171: Oceania Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 172: Oceania Drug Formulation Market Attractiveness Analysis, By Country Figure 173: Oceania Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 174: Oceania Drug Formulation Market Attractiveness, By Indication Figure 175: Oceania Drug Formulation Market Attractiveness, By End User Figure 176: Australia Market Value Proportion Analysis, 2021 Figure 177: Global Vs. Australia Growth Comparison, 2021 to 2032 Figure 178: Australia Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 179: Australia Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 180: Australia Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 181: New Zealand Market Value Proportion Analysis, 2021 Figure 182: Global Vs. New Zealand Growth Comparison, 2021 to 2032 Figure 183: New Zealand Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 184: New Zealand Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 185: New Zealand Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 186: Middle East & Africa Drug Formulation Market Value Share, By Dosage Form 2022 (E) Figure 187: Middle East & Africa Drug Formulation Market Value Share, By Indication 2022 (E) Figure 188: Middle East & Africa Drug Formulation Market Value Share, By End User 2022 (E) Figure 189: Middle East & Africa Drug Formulation Market Value Share, By Region 2022 (E) Figure 190: Middle East & Africa Drug Formulation Market Size (US$ Bn) Analysis, 2012 to 2021 Figure 191: Middle East & Africa Drug Formulation Market Size (US$ Bn) & Y-o-Y Growth (%) Analysis, 2022 to 2032 Figure 192: Middle East & Africa Drug Formulation Market Attractiveness Analysis, By Country Figure 193: Middle East & Africa Drug Formulation Market Attractiveness Analysis, By Dosage Form Figure 194: Middle East & Africa Drug Formulation Market Attractiveness, By Indication Figure 195: Middle East & Africa Drug Formulation Market Attractiveness, By End User Figure 196: GCC Countries Market Value Proportion Analysis, 2021 Figure 197: Global Vs. GCC Countries Growth Comparison, 2021 to 2032 Figure 198: GCC Countries Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 199: GCC Countries Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 200: GCC Countries Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 201: Turkey Market Value Proportion Analysis, 2021 Figure 202: Global Vs. Turkey Growth Comparison, 2021 to 2032 Figure 203: Turkey Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 204: Turkey Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 205: Turkey Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 206: Egypt Market Value Proportion Analysis, 2021 Figure 207: Global Vs. Egypt Growth Comparison, 2021 to 2032 Figure 208: Egypt Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 209: Egypt Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 210: Egypt Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 211: South Africa Market Value Proportion Analysis, 2021 Figure 212: Global Vs. South Africa Growth Comparison, 2021 to 2032 Figure 213: South Africa Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 214: South Africa Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 215: South Africa Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032 Figure 216: North Africa Market Value Proportion Analysis, 2021 Figure 217: Global Vs. North Africa Growth Comparison, 2021 to 2032 Figure 218: North Africa Drug Formulation Market Share Analysis (%), By Dosage Form, 2021 to 2032 Figure 219: North Africa Drug Formulation Market Share Analysis (%), By Indication, 2021 to 2032 Figure 220: North Africa Drug Formulation Market Share Analysis (%), By End User, 2021 to 2032
Recommendations
Explore Healthcare Insights
View Reports